Gb1211
WebGB1211 Chemistry Full Screen View Also known as: Schembl19680724, Gtpl11202, Gb-1211, Compound 11d [zetterberg et al., 2024], 2- (5-bromopyridin-3-yl)sulfanyl-6- (hydroxymethyl)-4- [4- (3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Molecular Formula C 19 H 16 BrF 3 N 4 O 4 S Molecular Weight 533.3 g/mol InChI Key FNCLKJPMEFPXOR … WebDec 13, 2024 · GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and had dose-dependent pharmacokinetics. About Galectin-3 in Liver Cirrhosis
Gb1211
Did you know?
WebKnow about technical details of GB1211 like: chemical name, chemistry structure, formulation, uses, toxicity, action, side effects and more at Pharmacompass.com. … WebSep 13, 2024 · GB1211 has the potential to treat multiple types of cancer and fibrotic diseases. Galecto’s initial target indications for GB1211 are NSCLC, a cancer indication …
WebGB1211 is also being studied in pts with hepatic impairment (NCT05009680). Trial design GALLANT-1 is a 3-part phase 1b/2a study that will investigate safety and efficacy of GB1211 + atz vs placebo + atz in pts with advanced or metastatic NSCLC that expresses PD-L1 on ≥50% of tumour cells. WebNov 2, 2024 · GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and had dose-dependent pharmacokinetics. About Galectin-3 in Oncology
WebMar 2, 2024 · If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely. IP authentication when working within your organization’s network. Login with a username/password associated to your organization’s account. Persisted access using your organization’s identifier ... WebFeb 28, 2024 · A Study to Compare Pharmacokinetics of GB1211 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT05747573
WebMay 26, 2024 · GB1211, Galecto’s orally active, potent and selective galectin-3 inhibitor candidate, is designed to block the galectin-3 carbohydrate recognition domain and reduce tumor resistance to PD-1/PD-L1...
WebSep 11, 2016 · GB1211 at 20 mg/kg twice daily reduced collagen accumulation by 36%. Conclusions: Small molecular weight and orally active inhibitors of galectin-3 reduce bleomycin-induced fibrosis when administered as a therapeutic dosing regimen. These inhibitors show promise as potential new oral anti-fibrotic agents for the treatment of … happy birthday yellow flowersWebDec 13, 2024 · GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients Galecto initiates Part 2 … happy birthday yorkshire terrier imagesWebSep 15, 2024 · GB1211, a potent oral small molecule galectin-3 inhibitor was well tolerated in human volunteer studies; Phase 2a study planned to establish the anti-fibrotic effects of GB1211 in grade 2 to 4 Non-Alcoholic SteatoHepatitis (NASH) Data presented at the American Chemical Society Meeting, Drug Discovery Chemistry and EFMC-ISMC chaliyama steel plant chaibasaWebGB1211 restored the binding of the anti-PD1/anti-PDL1 therapeutics and may thus reduce tumor resistance to these agents. These findings harmonize excellently with in vivo and clinical data showing an association between Gal-3 expression and lack of efficacy of PD-1/PD-L1 targeted checkpoint inhibitors. happy birthday you filthy animalWebGB1211 is a novel oral Gal-3 inhibitor which has shown potential in preclinical studies for reducing fibrosis. The GULLIVER-2 trial (NCT05009680) is an innovative, hybrid-design, … chalivoy-milonWebFeb 15, 2024 · Patients enrolled in part A may continue treatment with 200 mg GB1211 BID or 400 mg GB1211 BID and atezolizumab for 12 weeks, after which the patients will be … chaliyama steel plant chaibasa addressWebJun 16, 2024 · GB1211 has been shown to be a well-tolerated, potent inhibitor of galectin-3 with the potential to act as a monotherapy in solid tumors and enhance checkpoint inhibitor therapies,” said Dr Hans... chaliyar movement